Editorial: vedolizumab as a treatment and cause of extra‐intestinal manifestations of inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 535-536

John Wiley & Sons Inc

Access to resources Recommend Favorite

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 356-363

John Wiley & Sons Inc

Access to resources Recommend Favorite

Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management

By Larsen Signe   Bendtzen Klaus   Nielsen Ole Haagen  

Annals of Medicine, Vol. 42, Iss. 2, 2010-02 ,pp. : 97-114

Informa Healthcare

Access to resources Recommend Favorite

Prevalence of Epstein–Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 10, 2013-11 ,pp. : 1248-1254

John Wiley & Sons Inc

Access to resources Recommend Favorite

Modeling the role of genetic factors in characterizing extra-intestinal manifestations in Crohn's disease patients: does this improve outcome predictions?

By Giachino Daniela F.   Regazzoni Silvia   Bardessono Marco   De Marchi Mario   Gregori Dario    

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1657-1665

Informa Healthcare

Access to resources Recommend Favorite